SummitTX Capital’s Cidara Therapeutics CDTX Stock Holding History

SummitTX Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,149	Closed	-$2.24M	–	794
2025 Q4	$2.24M	Buy	+10,149	New	+$1.64M	0.07%	292
2025 Q3	–	Sell	-9,197	Closed	-$448K	–	782
2025 Q2	$448K	Buy	+9,197	New	+$221K	0.02%	530

SummitTX Capital's CDTX Position: Q1 2026 in Review

SummitTX Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 10,149 shares — an estimated $2.24M sold.

SummitTX Capital first reported a position in CDTX in Q2 2025 and held it in 2 quarters. The position peaked at $2.24M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

SummitTX Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 10,149 Cidara Therapeutics shares in Q1 2026, an estimated $2.24M.
SummitTX Capital first reported a position in Cidara Therapeutics in Q2 2025 and held it in 2 quarters.
SummitTX Capital's Cidara Therapeutics position peaked at $2.24M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.